COLORECTAL CARCINOMA IS ONE OF THE MOST PREVALENT AND LETHAL CANCERS IN THE UNITED STATES.

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$41,557.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
3053
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Granite Diagnostics
2990 Anthony Road, Burlington, NC, 27215
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 WILLIAM D. CLARK
 PRINCIPAL INVESTIGATOR
 (919) 226-6311
Business Contact
Phone: () -
Research Institution
N/A
Abstract
COLORECTAL CARCINOMA IS ONE OF THE MOST PREVALENT AND LETHAL CANCERS IN THE UNITED STATES. ACCORDING TO THE AMERICAN CANCER SOCIETY, THERE ARE 130,000 NEW CASES EACH YEAR. EARLY DIAGNOSIS IS DIFFICULT AND THERE IS NO DIAGNOSTIC TEST WITH A HIGH POSITIVE PREDICTIVE VALUE IN THE EARLY STAGES OF THE DISEASE. DEVELOPMENT OF A TEST THAT DETECTS EARLY COLORECTAL CARCINOMA WOULD SIGNIFICANTLY REDUCE MORBIDITY AND MORTALITY. TESTING THE FEASIBILITY OF A MONOCLONAL-BASED SERUM TEST FOR A COLORECTAL CARCINOMA MARKER IS NOW WARRANTED. MONOCLONAL ANTIBODIES GENERATED AGAINST CRUDE EXTRACTS OF COLORECTAL CARCINOMA CELLS OR FROM HOMOGENATES OF COLORECTAL CELL CULTURES HAVE BEEN PRODUCED BY A NUMBER OF DIFFERENT INVESTIGATORS. SOME MONOCLONAL ANTIBODIES WITH POTENTIAL FOR A RAPID TEST HAVE BEEN DEVELOPED BY CHAN'S GROUP AT M.D. ANDERSON. GRANITE DIAGNOSTICS PROPOSES TO EVALUATE THESE ANTIBODIES TO DETECT THE RELEVANT ANTIGEN(S) IN URINE AND/OR SERUM SAMPLES AND TO DEVELOP A TEST FOR EARLY DIAGNOSIS OF COLORECTAL CARCINOMA. FAVORABLE RESULTS IN PHASE I RESEARCH WILL LEAD TO PHASE II DEVELOPMENT AND TESTING OF A MARKETABLE KIT.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government